(:RARX)
Business Focus: N/A
Feb 28, 2020 07:00 am ET
Ra Pharmaceuticals Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13th Annual Rare Disease Day®, an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people living with rare diseases face.
Feb 27, 2020 07:00 am ET
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent corporate and clinical developments.
Feb 26, 2020 04:05 pm ET
CRISPR Therapeutics Proposes Changes to the Board of Directors
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Directors at the Company’s upcoming...
Feb 18, 2020 07:00 am ET
Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology. The JAMA Neurology publication can be accessed
Jan 22, 2020 09:00 am ET
Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the U.S. Food and Drug Administration’s (FDA) clearance of the Investigational New Drug (IND) application for the HEALEY ALS Platform Trial for the treatment of amyotrophic lateral sclerosis (ALS). Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General.
Dec 04, 2019 07:00 am ET
Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM).
Nov 25, 2019 11:30 pm ET
Rigrodsky & Long, P.A. Files Class Action Suit Against Ra Pharmaceuticals, Inc.
Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Ra Pharmaceuticals, Inc. (“Ra Pharmaceuticals”) (NASDAQ...
Nov 23, 2019 11:07 am ET
Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies Is Fair to Shareholders – RARX, IPHS, CISN, LPT
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Ra Pharmaceuticals, Inc. (NASDAQ: RARX) The investigation concerns whether Ra Pharmaceuticals and its board of directors violated the federal...
Nov 20, 2019 03:47 pm ET
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of United Community, Highlands, MB Bancorp, and Ra Pharmaceuticals on behalf of Stockholders and Encourages Inves
Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of United Community Financial Corp. (NASDAQ: UCFC), Highlands Bankshares, Inc. (Other OTC: HLND), MB Bancorp, Inc. (Other OTC:...
Nov 16, 2019 09:39 am ET
Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies Is Fair to Shareholders – WLH, CISN, RARX, TECD
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: William Lyon Homes (NYSE: WLH)The investigation concerns whether William Lyon and its board of directors violated the federal securities laws...
Nov 15, 2019 05:05 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, RARX, and IPHS Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway,...
Nov 11, 2019 03:37 pm ET
Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders – IPHS, INXN, RARX, VSI
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Innophos Holdings, Inc. (NASDAQ: IPHS) The investigation concerns whether Innophos and its board of directors violated the federal...
Nov 07, 2019 07:00 am ET
Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
“With the dosing of the first patient in our pivotal Phase 3 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG), as well as zilucoplan’s selection as one of the first therapeutic candidates to be evaluated in a pioneering platform trial for amyotrophic lateral sclerosis (ALS) sponsored by the Sean M. Healey & AMG Center for ALS at Mass General, we’ve made significant progress in executing against our strategic plan and expanding zilucoplan’s pipeline of neurologic, tissue-based, complement-mediated diseases,” said Doug Treco, Ph.D., President and Chief Execut
Nov 04, 2019 03:53 pm ET
Merger Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders – VSI, RARX, SRCI, UCFC
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Vitamin Shoppe, Inc. (NYSE: VSI)The investigation concerns whether Vitamin Shoppe and its board of directors violated the federal...
Nov 04, 2019 02:27 pm ET
MERGER ALERT – RARX, EMPK, and CETV: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Ra Pharmaceuticals, Inc. (NASDAQ: RARX)...
Nov 04, 2019 01:55 pm ET
Nov 01, 2019 06:26 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, and RARX Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th...
Nov 01, 2019 02:10 pm ET
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies Is Fair to Shareholders – RARX, ACHN, IPHS, CISN
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Ra Pharmaceuticals, Inc. (NASDAQ: RARX)The investigation concerns whether Ra Pharmaceuticals and its board of directors violated the federal...
Oct 29, 2019 03:02 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, ACHN, RARX Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th...
Oct 28, 2019 12:30 pm ET
MERGER ALERT – ACHN, RARX, and IPHS: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Achillion Pharmaceuticals, Inc. (NASDAQ:...
Oct 24, 2019 02:06 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Innophos Holdings, Inc. (NASDAQ GS: IPHS) regarding possible breaches of fiduciary duties and other violations of law related to Innophos’ agreement to be acquired by One Rock Capital...
Oct 23, 2019 04:27 pm ET
MERGER ALERT – RARX, DOVA, and SEMG: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Ra Pharmaceuticals, Inc. (NASDAQ: RARX)...
Oct 22, 2019 03:07 pm ET
Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – IPHS, ACHN, RARX, TSG
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Innophos Holdings, Inc. (NASDAQ: IPHS) The investigation concerns whether Innophos and its board of directors violated the federal securities...
Oct 17, 2019 01:56 pm ET
RARX, ROAN, and FCSC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Ra Pharmaceuticals, Inc. (NASDAQ GS: RARX) regarding possible breaches of fiduciary duties and other violations of law related to Ra Pharmaceutical’s agreement to be acquired by UCB S.A...
Oct 16, 2019 01:12 pm ET
MERGER ALERT – RARX, DOVA, and ROAN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Ra Pharmaceuticals, Inc. (NASDAQ: RARX)...
Oct 15, 2019 10:12 am ET
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – RARX, PGNX, TSG, ROAN
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Ra Pharmaceuticals, Inc. (NASDAQ: RARX)The investigation concerns whether Ra Pharmaceuticals and its board of directors violated the federal...
Oct 14, 2019 06:02 pm ET
RA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ra Pharmaceuticals, Inc. - RARX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ra Pharmaceuticals, Inc. (NasdaqGM: RARX) to UCB S.A. Under the terms of the proposed transaction, shareholders of Ra will receive only $48.00 in cash for each share of Ra that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 11, 2019 04:19 pm ET
STOCKHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Merger
NEW YORK, Oct. 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:
Oct 10, 2019 02:52 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Ra Pharmaceuticals, Inc. to UCB S.A. is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ra Pharmaceuticals, Inc. (“Ra Pharma” or the “Company”) (NASDAQ:RARX) stock prior to October 10, 2019. You are hereby...
Oct 10, 2019 02:24 pm ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on Behalf of Ra Pharma Shareholders and Encourages Ra Pharma Investors to Contact the Fir
NEW YORK, Oct. 10, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on behalf of Ra Pharma shareholders concerning the proposed merger with UBC SA.
Oct 10, 2019 02:21 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Ra Pharmaceuticals, Inc.
NEW YORK, Oct. 10, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Ra Pharmaceuticals, Inc. ("RARX" or the "Company") (NASDAQ: RARX) in connection with the proposed acquisition of the Company by UCB S.A. ("UCB"). Under the terms of the acquisition agreement, RARX shareholders will receive $48.00 for each RARX share they own.
Oct 10, 2019 12:54 pm ET
Ra Pharmaceuticals Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Ra Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Fir
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) to UCB S.A. (“UCB”) for $48.00 per share is fair to Ra shareholders. On behalf of Ra shareholders, Halper Sadeh LLP...
Oct 10, 2019 08:12 am ET
Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale of Ra Pharmaceuticals; Is $48 a Fair Price?
SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) ("Ra Pharma") breached their fiduciary duties in connection with the proposed sale of the Company to UCB S.A.
Oct 10, 2019 07:00 am ET
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
BRUSSELS and CAMBRIDGE, Massachusetts, Oct. 10, 2019 /PRNewswire/ --
Oct 10, 2019 01:22 am ET
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
regulated information – inside information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma. Under the terms of the agreement, Ra Pharma shareholders will receive US$ 48 in cash for each Ra Pharma share at closing. The Boards of Directors of both companies have unanimously approved the transaction, which remains subject to approval by Ra Pharma shareholders and to obtaining antitrust clearance and other customary closing conditions.
Oct 02, 2019 07:00 am ET
Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG).
Sep 18, 2019 07:00 am ET
Ra Pharmaceuticals Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the selection of zilucoplan as one of the first clinical candidates to be evaluated in a pioneering platform trial for amyotrophic lateral sclerosis (ALS), led by the Sean M. Healey & AMG Center for ALS at Mass General. The Healey Center has agreed to provide funding for the execution of the platform trial to support its goal of accelerating the development of effective treatments for patients with ALS.
Sep 04, 2019 07:00 am ET
Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis. Ra Pharma is developing zilucoplan, a self-administered macrocyclic peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis (g
Aug 21, 2019 07:00 am ET
Ra Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that it has earned a clinical development milestone under its collaboration agreement with Merck, known as MSD outside the U.S. and Canada. The milestone is associated with the dosing of the first patient in a Phase 1 clinical trial evaluating an investigational orally-available macrocyclic peptide for a non-complement cardiovascular target with a large market opportunity from the companies’ collaboration.
Aug 07, 2019 07:00 am ET
Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the second quarter ended June 30, 2019, and provided an update on recent corporate and clinical developments.
Jul 26, 2019 10:44 am ET
Ra Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the closing of an underwritten public offering of 4,600,000 shares of its common stock, at a public offering price of $32.50 per share, including 600,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were $149.5 million.
Jul 23, 2019 08:09 pm ET
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, at a public offering price of $32.50 per share. Ra Pharma also granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $130 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the sha
Jul 22, 2019 05:29 pm ET
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. Ra Pharma expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of its common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Ra Pharma.
Jul 16, 2019 07:00 am ET
Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) and Camurus AB (Nasdaq STO:CAMX) today announced an exclusive worldwide license agreement for the use of Camurus’s proprietary FluidCrystal® (FC) technology to develop, manufacture, and commercialize a long-acting formulation of zilucoplan, Ra Pharma’s complement component 5 (C5) inhibitor in development for the treatment of multiple complement-mediated disorders.
Jun 04, 2019 07:00 am ET
Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the U.S. Food and
Drug Administration’s (FDA) clearance of the Company’s Investigational
New Drug (IND) application for zilucoplan for the treatment of
immune-mediated necrotizing myopathy (IMNM). The Company is on track to
initiate a Phase 2 clinical trial in the second half of 2019.
May 28, 2019 07:00 am ET
Ra Pharmaceuticals to Present at Upcoming Investor Conferences
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) today announced that senior
management will present at the following upcoming investor conferences:
May 14, 2019 07:00 am ET
Ra Pharmaceuticals to Present at Upcoming Investor Conferences
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that senior
management will present at the following upcoming investor conferences:
May 09, 2019 07:00 am ET
Ra Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Ra
Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial
results for the first quarter ended March 31, 2019, and provided an
update on recent corporate and clinical developments.
May 07, 2019 07:00 am ET
Ra Pharmaceuticals Announces Positive gMG Phase 2 and Open-Label, Long-Term Extension Data at the 2019 AAN Annual Meeting
Ra
Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the presentation
of data from the Company’s Phase 2 clinical trial evaluating zilucoplan
for the treatment of generalized myasthenia gravis (gMG), including data
from the open-label, long-term extension study, at the 2019 American
Academy of Neurology (AAN) Annual Meet
Apr 24, 2019 06:30 am ET
Ra Pharmaceuticals Presents Pre-Clinical Data for Zilucoplan XR at the 6th Annual Peptides Congress
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today presented pre-clinical data
for an extended release (XR) formulation of zilucoplan at the 6th
Annual Peptides Congress, taking place April 24-25, 2019, in London, UK.
Apr 09, 2019 07:00 am ET
Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the successful
completion of End-of-Phase 2 interactions with the U.S. Food and Drug
Administration (FDA) for its Phase 3 clinical trial of zilucoplan for
the treatment of generalized myasthenia gravis (gMG).
Apr 01, 2019 04:05 pm ET
Ra Pharmaceuticals Announces Acceptance of gMG Phase 2 and Open-Label, Long-Term Extension Data for Emerging Science Dual Presentation at the 2019 AAN Annual Meeting
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that data from
its Phase 2 clinical trial of zilucoplan for the treatment of
generalized myasthenia gravis (gMG) have been selected for an Emerging
Science dual oral and poster presentation at the 2019 American Academy
of Neurology (AAN) Annual Meeting in Philadelphia, PA, from May 4 to 10,
2019. The presentation will feature data from the Phase 2, randomized,
double-blind, placebo-controlled clinical trial, as well as data from
the open-label, long-term extension study.
Mar 07, 2019 07:31 am ET
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Ra
Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial
results for the fourth quarter and year ended December 31, 2018, and
provided an update on recent corporate and clinical developments.
Mar 04, 2019 07:00 am ET
Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Doug Treco,
Ph.D., President and Chief Executive Officer of Ra Pharma, will present
at the Cowen 39th Annual Health Care Conference on Monday,
March 11, 2019 at 1:30 p.m. E.T. The conference is being held at Boston
Marriott Copley Place, Boston, MA.
Feb 28, 2019 07:00 am ET
Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today joins forces with 30
million healthcare advocates around the world for the 12th Annual Rare
Disease Day®, an awareness day dedicated to elevating public
understanding of rare diseases and calling attention to the special
challenges people living with rare diseases face.
Feb 21, 2019 07:00 am ET
Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Ramin
Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at
the 8th Annual SVB Leerink Global Healthcare Conference on Thursday,
February 28, 2019 at 2:30 p.m. E.T. The conference is being held at the
Lotte New York Palace, New York, NY.
Dec 11, 2018 06:32 pm ET
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced
the pricing of an underwritten public offering of 8,387,097 shares of
its common stock, at a public offering price of $15.50 per share, before
underwriting discounts and commissions. Ra Pharma also granted the
underwriters a 30-day option to purchase up to an additional 1,258,064
shares of its common stock. The gross proceeds from the offering, before
deducting underwriting discounts and commissions and estimated offering
expenses, are expected to be approximately $130.0 milli
Dec 10, 2018 04:01 pm ET
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced
that it intends to offer and sell, subject to market and other
conditions, $100 million of its common stock in an underwritten public
offering. Ra Pharma expects to grant the underwriters a 30-day option to
purchase up to $15 million of additional shares of its common stock.
Dec 10, 2018 07:00 am ET
Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced positive top-line
results from the Company’s Phase 2 clinical trial evaluating zilucoplan
for the treatment of generalized myasthenia gravis (gMG), achieving
clinically meaningful and statistically significant reductions in both
the primary and key secondary endpoints for both zilucoplan dose groups
tested versus placebo at 12 weeks. Zilucoplan dosed at 0.3 mg/kg
subcutaneously (SC) daily achieved a mean reduction from baseline of 6.0
points in the Quantitative Myasthenia Gravis (QMG) score
Dec 06, 2018 07:30 am ET
Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it has
received a development milestone payment under its collaboration
agreement with Merck, known as MSD outside the US and Canada. The
milestone payment is associated with the companies’ collaboration for a
non-complement cardiovascular target with a large market opportunity.
Initiated in 2013, this collaboration leverages Ra Pharma’s Extreme
Diversity™ platform aimed at producing macrocyclic peptides that have
the diversity and specificity of antibodies, while retaining the
p
Nov 15, 2018 07:30 am ET
Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of
Bo Cumbo to its board of directors. Mr. Cumbo is a veteran of the
biotechnology industry and has played strategically important roles in
the successful launch of 11 products across multiple organizations and
therapeutic categories, including rare neuromuscular diseases,
hepatitis, HIV, and cardiovascular disease.
Nov 07, 2018 05:17 pm ET
ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Add after last paragraph of release: two financial tables.
Nov 06, 2018 07:30 am ET
Ra Pharmaceuticals to Present at Upcoming Investor Conferences
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that senior
management will present at the following upcoming investor conferences:
Sep 26, 2018 07:30 am ET
Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced positive results
from the Company’s Phase 1b pharmacokinetic (PK) study evaluating
zilucoplan (RA101495 SC) in patients with renal impairment. The Company
has received International Nonproprietary Names (INN) clearance for use
of the name zilucoplan from the World Health Organization.
Sep 25, 2018 04:05 pm ET
Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Doug Treco,
PhD, President and Chief Executive Officer of Ra Pharma, will present at
the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018
at 9:10 a.m. E.T. The conference is being held at the InterContinental
New York Barclay Hotel.
Sep 25, 2018 07:30 am ET
Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of
Aoife M. Brennan, M.B., B.Ch., to its board of directors.
Sep 05, 2018 07:30 am ET
Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the completion of
End-of-Phase 2 interactions with the U.S. Food and Drug Administration
(FDA) for its global Phase 3 program of RA101495 SC for the treatment of
paroxysmal nocturnal hemoglobinuria (PNH).
Aug 15, 2018 08:25 am ET
Report: Developing Opportunities within RA PHARMCTL INC, Oclaro, Emergent Biosolutions, Kennametal, Instructure, and Donegal Group — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RA PHARMCTL INC (NASDAQ:RARX), Oclaro, Inc. (NASDAQ:OCLR), Emergent...
Aug 08, 2018 07:15 am ET
Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results
for the second quarter ended June 30, 2018 and highlighted recent
progress in advancing its pipeline programs, including RA101495 SC for
the treatment of generalized myasthenia gravis (gMG), paroxysmal
nocturnal hemoglobinuria (PNH), and complement-mediated renal diseases
such as atypical hemolytic uremic disorder (aHUS), and its
first-in-class, orally bioavailable, small molecule C5 inhibitor program.
Jun 15, 2018 07:00 am ET
Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the presentation
of scientific data at the 23rd Congress of the European
Hematology Association (EHA), June 14-17, 2018 in Stockholm, Sweden.
Jun 05, 2018 07:00 am ET
Ra Pharmaceuticals to Present at the 4th Congress of the European Academy of Neurology
“Complement C5 is a validated target for treating gMG, but currently
available options are difficult to access, and the need for high-volume
intravenous infusions places a burden on patients suffering with this
lifelong disease. This creates an opportunity to deliver a more
convenient, accessible therapy such as RA101495 SC to benefit a larger
population of patients with gMG,” said Ramin Farzaneh-Far, MD, Chief
Medical Officer of Ra Pharma. “As a once-daily, low-volume, subcutaneous
(SC), self-administered therapy, we believe RA101495 SC has the
May 31, 2018 07:00 am ET
Ra Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced that Doug Treco, Ph.D., President and Chief Executive Officer,
will present at the Jefferies 2018 Global Healthcare
Conference on Thursday, June 7, 2018 at 4:00 p.m. E.T. in New York.
May 24, 2018 08:30 am ET
Research Report Identifies Brady, RA PHARMCTL INC, Sigma Designs, Teva Pharmaceutical Industries, Bridge, and BOK Financial with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brady Corporation (NYSE:BRC), RA PHARMCTL INC (NASDAQ:RARX), Sigma...
May 17, 2018 09:48 am ET
Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that data from
the Company’s oral, small molecule, complement C5 inhibitor program and
data from the Company’s global, Phase 2 clinical program evaluating
RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria
(PNH) will be presented at the 23rd Congress of the European
Hematology Association (EHA) from June 14-17, 2018 in Stockholm, Sweden.
May 09, 2018 04:30 pm ET
Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced financial results
for the first quarter ended March 31, 2018 and provided an update on
recent corporate and clinical developments.
May 01, 2018 07:00 am ET
Ra Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced that Doug Treco, Ph.D., President and Chief Executive Officer,
will present at the Deutsche Bank 43rd An
Apr 25, 2018 07:00 am ET
Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that the design
of its Phase 2 clinical trial of RA101495 SC as a treatment for
generalized myasthenia gravis (gMG) will be presented in an oral
platform presentation at the 70th Annual American Academy of
Neurology (AAN), taking place April 21-27, 2018 in Los Angeles.
Apr 18, 2018 07:00 am ET
Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced the appointment of John C. King as Chief Commercial Officer,
effective April 16, 2018. Mr. King brings to Ra Pharma more than 20
years of senior, global, commercial leadership experience within the
biotechnology rare disease space, most recently with Alexion
Pharmaceuticals.
Apr 02, 2018 08:15 am ET
Recent Analysis Shows Jack Henry & Associates, Omnicell, Surgery Partners, Floor & Decor, NVE, and RA PHARMCTL INC Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Jack Henry & Associates, Inc. (NASDAQ:JKHY),...
Mar 14, 2018 04:15 pm ET
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focused on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced financial results for the fourth quarter and year ended
December 31, 2017 and provided an update on recent corporate
Mar 07, 2018 07:00 am ET
Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced that Doug Treco, Ph.D., President and Chief Executive Officer,
will present at the Cowen and Company 38th Annual Health Care
Conference on Wednesday, March 14, 2018 at 8:40 a.m. E.T. The conference
is being held at the Boston Marriott Copley Place.
Mar 01, 2018 04:09 pm ET
Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN Meeting
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced that the design of its Phase 2 clinical trial of RA101495 SC
for the treatment of generalized myasthenia gravis (gM
Feb 28, 2018 07:00 am ET
Ra Pharma Supports 11th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
joins forces with 30 million health care advocates around the world for
the 11th annual Rare Disease Day®. Rare Disease Day, which is
always the last day of February, is an annual awareness day dedicated to
elevating public understanding of rare diseases and calling attention to
the special challenges people living with rare diseases face
Feb 15, 2018 07:00 am ET
Ra Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced that Doug Treco, Ph.D., President and Chief Executive Officer,
will present at the RBC Capital Markets 2018 Global
Feb 14, 2018 09:13 am ET
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (NASDAQ: RARX) (“Ra Pharma”) today announced
the pricing of an underwritten public offering of 8,400,000 shares of
its common stock at a public offering price of $6.00 per share, before
underwriting discounts. Ra Pharma also granted the underwriters a 30-day
option to purchase up to an additional 1,260,000 shares of common stock.
The gross proceeds from the offering, before deducting underwriting
discounts and estimated offering expenses, are expected to be $50.4
million, excluding any exercise of the underwriters' optio
Feb 13, 2018 05:44 pm ET
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX) (“Ra Pharma”) today announced
that it intends to offer and sell, subject to market and other
conditions, $50 million of its common stock in an underwritten public
offering. Ra Pharma expects to grant the underwriters a 30-day option to
purchase up to $7.5 million of additional shares o
Feb 12, 2018 07:00 am ET
Jan 30, 2018 08:20 am ET
New Research: Key Drivers of Growth for VAREX IMAGING, DCP Midstream Partners, LP, Werner Enterprises, K12, RA PHARMCTL INC, and TOCAGEN INC — Factors of Influence, Major Initiatives and Sustained Pro
NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of VAREX IMAGING (NASDAQ:VREX), DCP Midstream Partners,...
Jan 08, 2018 07:12 am ET
Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it has
initiated dosing in the Company’s Phase 1b clinical trial evaluating
RA101495 SC in patients with renal impairment. This trial is designed to
characterize the pharmacokinetics (PK) of RA101495 SC in these patients,
thereby enabling the evaluation of RA101495
Dec 21, 2017 04:01 pm ET
Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it has
initiated dosing in the Company’s Phase 2 clinical trial evaluating
RA101495 SC for the treatment of generalized myasthenia gravis (gMG).
gMG is a rare, complement-mediated, autoimmune disease that causes
weakness in skeletal muscles. Ra Pharma is a clinical
Dec 07, 2017 07:12 am ET
Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced that Doug Treco, Ph.D., President and Chief Executive Officer,
will participate in a fireside chat at the BMO Capit
Dec 04, 2017 07:00 am ET
Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria
Ra
Pharmaceuticals, Inc. (NASDAQ: RARX) today announced positive
interim results from the Company’s ongoing, global Phase 2 clinical
program evaluating RA101495 SC for the treatment of paroxysmal nocturnal
hemoglobinuria (PNH). Ra Pharma is a clinical stage biopharmaceutical
company focusing on the development of next-gener
Nov 09, 2017 04:22 pm ET
Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced financial results for the third quarter ended September 30,
2017, and provided an update on recent corporate and cl
Oct 31, 2017 07:12 am ET
Ra Pharmaceuticals to Present at Upcoming Investor Conferences
Ra
Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of next-generation
therapeutics for the treatment of complement-mediated diseases, today
announced that Doug Treco, Ph.D., President and Chief Executive Officer,
will present at the following upcoming investor conf
Oct 27, 2016 12:30 pm ET
Nasdaq Welcomes Ra Pharmaceuticals Inc. (Nasdaq: RARX) to The Nasdaq Stock Market
Ra Pharmaceuticals Inc. (Nasdaq: RARX) Rings The Nasdaq Stock Market Opening Bell in Celebration of IPONEW YORK, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Ra Pharmaceuticals Inc. (Nasdaq:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market on October 26, 2016....
Oct 27, 2016 06:00 am ET
Ra Pharmaceuticals Inc. (Nasdaq: RARX) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
ADVISORY, Oct. 27, 2016 (GLOBE NEWSWIRE) -- ...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.